New Results

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies

Hao Zhou, Takuya Tada, Belinda M. Dcosta, Nathaniel R. Landau
doi: https://doi.org/10.1101/2022.02.15.480166

Article Information

doi 
https://doi.org/10.1101/2022.02.15.480166
History 
  • February 24, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Hao Zhou1,*,
  2. Takuya Tada1,*,
  3. Belinda M. Dcosta1,* and
  4. Nathaniel R. Landau1,#
  1. 1Department of Microbiology, NYU Grossman School of Medicine, New York, NY, USA
  1. ↵#Corresponding author: Nathaniel R. Landau, Ph.D., NYU Grossman School of Medicine, 430 East 29th Street, Alexandria West Building, Rm 509, New York, NY 10016, Email: nathaniel.landau{at}med.nyu.edu, Phone: (212) 263-9197

  1. ↵* These authors contributed equally.

Back to top
Posted February 24, 2022.
Download PDF
Email
Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies
Hao Zhou, Takuya Tada, Belinda M. Dcosta, Nathaniel R. Landau
bioRxiv 2022.02.15.480166; doi: https://doi.org/10.1101/2022.02.15.480166
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area